An inactivated gE-negative marker vaccine and an experimental gD-subunit vaccine reduce the incidence of bovine herpesvirus 1 infections in the field

Vaccine

Volumn 16, Issue 2-3, 1998, Pages 265-271

  Bosch, J C ^a   De Jong, M C M ^b   Franken, P ^c   Frankena, K ^b   Hage, J J ^c   Kaashoek, M J ^b   Maris Veldhuis, M A ^b   Noordhuizen, J P T M ^b   Van Der Poel, W H M ^d   Verhoeff, J ^c   Weerdmeester, K ^b   Zimmer, G M ^c   Van Oirschot, J T ^b  

^a HG   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c GD ANIMAL HEALTH   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES VACCINE; PLACEBO;

ANIMAL EXPERIMENT; ARTICLE; CATTLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HERPES SIMPLEX VIRUS 1; INCIDENCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; VIRUS TRANSMISSION;

ANIMALS; ANTIGENS, VIRAL; CATTLE; CATTLE DISEASES; FEMALE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, BOVINE; VACCINATION; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0031986228     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00166-7     Document Type: Article

References (31)

1. 1 Vab Oirschot, J.T., Straver, P.J., Van Lieshout, J.A.H., Quak, J., Westenbrink, F. and Van Exsel, A.C.A. A widespread subclinical infection of bulls with bovine herpesvirus type 1 at an artificial insemination centre. Vet. Rec. 1993, 132, 32-35.
2. 2 Ackermann, M., Peterhans, E., and Wyler, R. DNA of bovine herpesvirus type 1 in the trigeminal ganglia of latently infected calves. Am. J. Vet. Res. 1982, 43, 36-40.
3. 3 Van Engelenburg, F.A.C., Van Schie, F.W., Rijsewijk, F.A.M. and Van Oirschot, J.T. Excretion of bovine herpesvirus 1 in semen is detected much longer by PCR than by virus isolation. J. Clin. Microbiol. 1995, 33, 308-312.
4. 4 Hage, J.J., Schukken, Y.H., Barkema, H.W., Benedictus, G., Rijsewijk, F.A.M. and Wentink, G.H. Population dynamics of envi infection in a dairy herd. Vet. Microbiol. 1996, 53, 169-180.
5. 5 Van Wuyckhuise, L., Bosch, J.C., Franken, P., Hage, J., Verhoeff, J. and Zimmer, G. The prevalence of IBR in the Netherlands. The Kenya Veterinarian 1994, 18, 479-483.
6. 6 Frerichs, G.N., Woods, S.B., Lucas, M.H. and Sands, J.J. Safety and efficacy of live and inactivated infectious bovine rhinotracheitis vaccines. Vet. Rec. 1982, 111, 116-122.
7. 7 Van Oirschot, J.T., Kaashoek, M.J., Rijsewijk, F.A.M. and Stegeman, J.A. The use of marker vaccines in eradication of herpesvirus J. Biotechn. 1996, 44, 75-81.
8. 8 De Jong, M.C.M. and Kimman, T.G. Experimental quantification of vaccine-induced reduction in virus transmission. Vaccine 1994, 12, 761-766.
9. 9 Stegeman, J.A., Tielen, M.J.M., Kimman, T.G., Van Oirschot, J.T., Hunneman, W.A. and Berndsen, F.W. Intensive regional vaccination with a ge-deleted vaccine markedly reduces pseudorabies virus infections. Vaccine 1994, 12, 527-531.
10. 10 Flores, E.F., Osorio, F.A., Zanella, E.L., Kit, S. and Kit, M. Efficacy of a deletion mutant bovine herpesvirus-1(BHV-1) vaccine that allows serologic differentiation of vaccinated from naturally infected animals. J. Vet. Diagn. Invest. 1993, 5, 534-540.
11. 11 Kaashoek, MJ., Moerman, A. and Madic, J. et al. A conventionally attenuated gE-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine. Vaccine 1994, 12, 439-444.
12. 12 Kaashoek, M.J., Moerman, A. and Madic, J. et al. An inactivated vaccine based on a glycoprotein E-negative strain of bovine herpesvirus 1 induces protective immunity and allows serological differentiation. Vaccine 1995, 13, 342-346.
13. 13 Drunen Littel-van den Hurk, S., Van Donkersgoed, J. and Kowalski, J. et al. A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus 1 in cattle. Vaccine 1994, 12, 1295-1302.
14. 14 Bosch J.C., De Jong, M.C.M., Maissan, J. and van Oirschot, J.T. Quantification of experimental transmission of bovine herpesvirus 1 in cattle vaccinated with marker vaccines. Bovine Practitioner 1997, 31, 49-50.
15. 0 in models of infectious diseases in heterogeneous populations. J. Math. Biol. 1990, 28, 365-382.
16. 16 Van Oirschot, J.T., Bosch, J.C., Kaashoek, M.J. and Rijsewijk, F.A.M. Advances towards the eradication of herpesviruses by the use of marker vaccines. Bull. Soc. Franco-Japonaise Sci. Vet. 1995, 2, 106-112.
17. 17 Halloran, M.E., Haber, M., Longini , I.M. and Struchiner, J. Direct and indirect effects in vaccine efficacy and vaccine effectiveness. Am. J. Epidemiol. 1991, 133, 323-331.
18. 18 Cracknell, V. The development of clinical data on veterinary medical products in the European Community. A viewpoint from industry. In: Field Trial and Error, Proceedings of the International Seminar on the Design, Conduct and Interpretation of Field Trials. Berg and Dal, The Netherlands, April 1993, pp. 97-99.
19. 19 Bosch, U.C., Frankena, K. and Van Oirschot, J.T. Effect on milk production of vaccination with a bovine herpesvirus gene-deleted vaccine. Veterinary Research 1997, 140, 196-199.
20. 20 Strube, W., Abar, B., Bergle, R.D. et al. Infectious Bovine Rhiinotracheitis marker vaccines - chemically inactivated and live attenuated - for the improvement of BHV1 control programs: 1. Safety aspects in the vaccine development. In: Proceedings XVIII World Buiatrics Congress, Bologna, Italy, 1994, Vol. 2, pp. 757-760.
21. 21 Strube, W., Abar, B., Bergle, R.D. et al. Infectious Bovine Rhinotracheitis marker vaccines - chemically inactivated and live attenuated - for the improvement of BHV1 control programs: 2. Evaluation of immunogenicity. In: Proceedings XVIII World Buiatrics Congress, Bologna, Italy, 1994, Vol. 2, pp. 761-764.
22. 22 Van Oirschot, J.T., Kaashoek, M.J., Maris-Veldhuis, M.A., Weerdmeester, K. and Rijsewijk, F.A.M. An enzyme linked immunosorbent assay to detect antibodies against glycoprotein E of bovine herpesvirus 1 allows differentiation between infected and vaccinated cattle. In: Journal of Virological Methods, in press.
23. 23 De Jong, M.C.M., Van Leengoed, L.A.M.G., Wensvoort, G., Terpstra, C. and Verheijden, J.H.M. Population biological studies of the Porcine Epidemic Abortion and Respiratory Syndrome (PEARS) before and after isolation of the Lelystad Virus. In: VEEC Proceedings, Utrecht, 1991, pp. 1-16.
24. 24 Becker, N. Analysis of Infectious Disease Data. Chapman and Hall, London, 1989.
25. 25 Bouma, A., De Jong, M.C.M. and Kimman, T.G. Transmission of pseudorabies virus within populations is independent of the size of the population. Prev. Vet. Med. 1995, 23, 163-172.
26. 26 Statistix User's Manual, version 4.0. Analytic Software, St Paul, MN, USA.
27. 27 Fisher, R.A. Statistical Methods for Research Workers. Oliver & Boyd, Edinborough, 1954, p. 356.
28. 28 Van Nieuwstadt, A.P. and Verhoeff, J. Epidemiology of BHV1 virus infections in dairy herds. J. Hyg. Camb. 1983, 91, 309-318.
29. 29 Van Wuyckhuise, L. and Bosch, J.C. Epidemiologie characteristics of BHV1 infections in Dutch dairy herds. In: Proceeding SVEPM Conference Glasgow 1996, p. 30.
30. 30 Bosch, J.C., Kaashoek, M.J., Kroese, A.H. and Van Oirschot, J.T. An attenuated bovine herpesvirus 1 marker vaccine induces a better protection than two inactivated marker vaccines. Vet. Microbiol. 1996, 52, 223-234.
31. 31 Bosch, J.C., Kaashoek, M.J. and Van Oirschot, JT. Inactivated BHV1 marker vaccines are more efficacious in reducing field virus excretion after reactivation than a live BHV1 marker vaccine. Vaccine 1997, 15, 1512-1517.